Log in to save to my catalogue

Teclistamab in Relapsed or Refractory Multiple Myeloma

Teclistamab in Relapsed or Refractory Multiple Myeloma

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_swepub_ki_se_452942

Publication information

Publisher

United States: Massachusetts Medical Society

Subjects

Subjects and topics

More information

Scope and Contents

Contents

In this phase 1–2 study involving patients with relapsed or refractory myeloma, a bispecific antibody (teclistamab) that mediates T-cell activation and subsequent lysis of myeloma cells expressing B-cell maturation antigen induced responses in 63% of the patients, including a complete response in nearly 40%.

Alternative Titles

Full title

Teclistamab in Relapsed or Refractory Multiple Myeloma

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_swepub_primary_oai_swepub_ki_se_452942

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_swepub_ki_se_452942

Other Identifiers

ISSN

0028-4793,1533-4406

E-ISSN

1533-4406

DOI

10.1056/NEJMoa2203478

How to access this item